286 related articles for article (PubMed ID: 28248292)
21. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers.
Moritoki Y; Lian ZX; Wulff H; Yang GX; Chuang YH; Lan RY; Ueno Y; Ansari AA; Coppel RL; Mackay IR; Gershwin ME
Hepatology; 2007 Feb; 45(2):314-22. PubMed ID: 17256753
[TBL] [Abstract][Full Text] [Related]
22. Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.
Hu L; Wang T; Gocke AR; Nath A; Zhang H; Margolick JB; Whartenby KA; Calabresi PA
PLoS One; 2013; 8(1):e54267. PubMed ID: 23382885
[TBL] [Abstract][Full Text] [Related]
23. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
24. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
25. The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.
Chen YJ; Lam J; Gregory CR; Schrepfer S; Wulff H
PLoS One; 2013; 8(11):e81006. PubMed ID: 24312257
[TBL] [Abstract][Full Text] [Related]
26. Regulation of T Lymphocyte Functions through Calcium Signaling Modulation by Nootkatone.
Lee JM; Kim J; Park SJ; Nam JH; Kim HJ; Kim WK
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791278
[TBL] [Abstract][Full Text] [Related]
27. Blockage of K(Ca)3.1 and Kv1.3 channels of the B lymphocyte decreases the inflammatory monocyte chemotaxis.
Zhang S; Wang X; Ju C; Zhu L; Du Y; Gao C
Int Immunopharmacol; 2016 Feb; 31():266-71. PubMed ID: 26795234
[TBL] [Abstract][Full Text] [Related]
28. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
Valverde P; Kawai T; Taubman MA
J Dent Res; 2005 Jun; 84(6):488-99. PubMed ID: 15914584
[TBL] [Abstract][Full Text] [Related]
29. K
Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
[TBL] [Abstract][Full Text] [Related]
30. Targeting effector memory T-cells with Kv1.3 blockers.
Wulff H; Pennington M
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
[TBL] [Abstract][Full Text] [Related]
31. Periodic Membrane Potential and Ca
Papp F; Hajdu P; Tajti G; Toth A; Nagy E; Fazekas Z; Kovacs S; Vámosi G; Varga Z; Panyi G
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106594
[TBL] [Abstract][Full Text] [Related]
32. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.
Gocke AR; Lebson LA; Grishkan IV; Hu L; Nguyen HM; Whartenby KA; Chandy KG; Calabresi PA
J Immunol; 2012 Jun; 188(12):5877-86. PubMed ID: 22581856
[TBL] [Abstract][Full Text] [Related]
33. T-lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in the neonate.
Toldi G; Treszl A; Pongor V; Gyarmati B; Tulassay T; Vásárhelyi B
Int Immunol; 2010 Sep; 22(9):769-74. PubMed ID: 20601376
[TBL] [Abstract][Full Text] [Related]
34. Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.
Zhao N; Dong Q; Qian C; Li S; Wu QF; Ding D; Li J; Wang BB; Guo KF; Xie JJ; Cheng X; Liao YH; Du YM
Sci Rep; 2015 Nov; 5():17381. PubMed ID: 26616555
[TBL] [Abstract][Full Text] [Related]
35. The Ca(2+)-activated K(+) channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes.
Nicolaou SA; Neumeier L; Peng Y; Devor DC; Conforti L
Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1431-9. PubMed ID: 17151145
[TBL] [Abstract][Full Text] [Related]
36. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
37. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
Orbán C; Bajnok A; Vásárhelyi B; Tulassay T; Toldi G
Cytometry A; 2014 Jul; 85(7):636-41. PubMed ID: 24827427
[TBL] [Abstract][Full Text] [Related]
38. Anti-Inflammatory Effect of Licochalcone A via Regulation of ORAI1 and K
Phan HTL; Kim HJ; Jo S; Kim WK; Namkung W; Nam JH
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639190
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation.
Conforti L; Petrovic M; Mohammad D; Lee S; Ma Q; Barone S; Filipovich AH
J Immunol; 2003 Jan; 170(2):695-702. PubMed ID: 12517930
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of human beta-defensins 3 and 4 on potassium channels: Evidence of diversity in beta-defensin-potassium channel interactions.
Zhao Y; Xie Z; Feng J; Li W; Cao Z; Wu Y
Peptides; 2018 Oct; 108():14-18. PubMed ID: 30121363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
